(Q37728653)

22 August 2017

1 reference

title

Early recognition and prevention of chronic kidney disease (English)

1 reference

22 August 2017

Marcello Tonelli

3

0 references

Brenda R. Hemmelgarn

series ordinal

2

object named as

Brenda R Hemmelgarn

1 reference

22 August 2017

Matthew T James

1

1 reference

PubMed ID

20382326

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

375

1 reference

22 August 2017

9722

1 reference

22 August 2017

1296-1309

1 reference

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Guidelines for the management of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Early identification and management of chronic kidney disease: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prevalence and factors associated with CKD: a population study from Beijing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Staging of chronic kidney disease: time for a course correction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prevalence of chronic kidney disease in population-based studies: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The growing burden of chronic kidney disease in Pakistan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prevalence of chronic kidney disease in the Japanese general population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

International comparison of the relationship of chronic kidney disease prevalence and ESRD risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease in the elderly: is it really a premise for overwhelming renal failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Risk factors for end-stage renal disease: 25-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Predictors of new-onset kidney disease in a community-based population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Association between obesity and kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease in the developing world.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

How can we achieve global equity in provision of renal replacement therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The changing patterns of chronic kidney disease: the need to develop strategies for prevention relevant to different regions and countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Definition of Kidney Dysfunction as a Cardiovascular Risk Factor Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Extended prognostic value of urinary albumin excretion for cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The risk of acute renal failure in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

A population-based study of the incidence and outcomes of diagnosed chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Population-based screening for CKD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Screening for proteinuria in US adults: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Kidney disease screening program in Japan: history, outcome, and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The Kidney Early Evaluation Program (KEEP): program design and demographic characteristics of the population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Prevention programmes of progressive renal disease in developing nations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

UK Consensus Conference on Early Chronic Kidney Disease--6 and 7 February 2007

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Reporting estimated GFR: a laboratory perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

eGFR: is it ready for early identification of CKD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Screening for CKD with eGFR: doubts and dangers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The impact of automated eGFR reporting and education on nephrology service referrals.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Blood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The frequency of hyperkalemia and its significance in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Major congenital malformations after first-trimester exposure to ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effect of telmisartan on renal outcomes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Long-term effects of antihypertensive agents on proteinuria and renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Statins for improving renal outcomes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease adversely influences patient safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Guided medication dosing for inpatients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Low protein diets for chronic kidney disease in non diabetic adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Bicarbonate supplementation slows progression of CKD and improves nutritional status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The association among smoking, heavy drinking, and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Lifestyle factors, obesity and the risk of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Body mass index and risk for end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Changes in body weight predict CKD in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Chronic kidney disease management in the United Kingdom: NEOERICA project results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Nephrologist care and mortality in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

An economic evaluation of early versus late referral of patients with progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Role of remission clinics in the longitudinal treatment of CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

Effects of multidisciplinary case management in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962004-3

7 January 2021

10.1016/S0140-6736(09)62004-3

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkaxnjj47rhm5cko7s6vd2lvvm

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_wkaxnjj47rhm5cko7s6vd2lvvm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkaxnjj47rhm5cko7s6vd2lvvm

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/wkaxnjj47rhm5cko7s6vd2lvvm

30 July 2022